Advertisement

Topics

Merz Pharma GmbH & Co. KGaA Company Profile

12:03 EDT 24th March 2019 | BioPortfolio


News Articles [1230 Associated News Articles listed on BioPortfolio]

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and ...

Merz Presents Key Findings Showcasing Five-Year Effectiveness of Cellfina® on Cellulite ...

Merz is also presenting key updates on leading aesthetics products including XEOMIN®, RADIESSE® and DESCRIBE®, with 15 presentations total Read more...

Merz Pharma GmbH Co KgaA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryMerz Pharma GmbH Co KgaA Merz Pharma is an aesthetics and neurotoxin company that develops products for aesthetic and medical dermatology and neurological movement disorders. The company's pro...

Physiomics’ annual revenue doubles thanks to lucrative Merck KGaA contract win

On top of the Merck KGaA win, Physiomics inked deals with several other pharma and biotech groups last year

#news #biotech Vertex strikes deal with Merck KGaA to grow CRISPR/Cas9 toolkit

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Vertex strikes deal with Merck KGaA to grow CRISPR/Cas9 toolkit .Vertex has r...

Merz to Present New Aesthetics Clinical Data at IMCAS 2019

Merz, a global leader in aesthetics and neurotoxins, announced today that clinical data on the use of the Merz Aesthetics portfolio, including Bocouture®, Belotero®, Cellfina®,...

JPMorgan belässt Merck KGaA auf 'Neutral'

Die US-Bank JPMorgan hat die Aktie der Merck KGaA auf "Neutral" belassen. Der Pharma- und Chemiekonzern habe drei Monate früher als erwartet positive klinische Studiendaten für eine Kombinationsth.....

ANALYSE-FLASH: Commerzbank hebt Ziel für Merck KGaA auf 111 Euro - 'Buy'

Die Commerzbank hat das Kursziel für Merck KGaA nach Quartalszahlen von 100 auf 111 Euro angehoben und die Einstufung auf "Buy" belassen. Der Pharma- und Chemiekonzern habe operative Stärke gezeig.....

Drugs and Medications [84 Associated Drugs and Medications listed on BioPortfolio]

La prairie switzerland [juvena produits de beaute gmbh]

Package.Label Principle Display Panel

Tobramycin [holopack verpackungstechnik gmbh]

Tobramycin Inhalation Solution (300 mg/5 mL)

Lonhala [holopack verpackungstechnik gmbh]

Glycopyrrolate Inhalation Solution (25 µg/mL)

Naftin [merz pharmaceuticals, llc]

NAFTIN NAFTIFINE HCl 1%

Etoposide [thymoorgan gmbh pharmazir & co. k.g]

Etoposide Injection, USP

PubMed Articles [37 Associated PubMed Articles listed on BioPortfolio]

Establishing and Maintaining a Robust Sample Management System.

This paper has been written by the SLAS Sample Management Special Interest Group to serve as a guide to the best practices and methods in establishing and maintaining a high-quality sample management ...

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

CVS and the $100,000 QALY.

The PBM unit of the health giant CVS decided that any new drug exceeding $100,000 per quality-adjusted life year (QALY) may be excluded from the formularies that are maintained by its clients. Patient...

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the dea...

Clinical Trials [135 Associated Clinical Trials listed on BioPortfolio]

Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects

This study are two-way crossover, open-label, single-dose, fasting, bioequivalence study of Memantinol® (JSC "GEROPHARM", Russia) 20 mg tablets versus Akatinol Memantine® (Merz Pharma Gm...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex®, Tablets, 160 mg (Bristol-Myers Squibb GmbH& CО. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions

This is an open-label, randomized, single-center, single-dose, two-treatment, two-sequence, two-period, crossover, comparative study, where each subject was randomly assigned to the refere...

Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation

Primary objective: - To evaluate the sensitivity of the Merz Lip Fullness Assessment Scale (MLFAS). Secondary objectives: - To evaluate the clinical aesthetic improvement outco...

Companies [1333 Associated Companies listed on BioPortfolio]

Merz Pharma GmbH & Co. KGaA

Merz Pharma Canada Ltd.

Merz Pharma Canada Ltd. a wholly owned subsidiary of the Merz Group of Companies was established in 2009 to expand Merz franchises in the Canadian Marketplace.

Merz Pharma Group Merz Pharma Group

The Merz Pharma Group’s focus is on drugs for treating neurological and psychiatric conditions and the group holds a leading position in the field of Alzheimer’s researc...

Merz Aesthetics

Merz Aesthetics, the new business unit of Merz Pharma Group, is a leader in the global aesthetic medicine market. With a 100-year history of compassion and innovation in healthcare, Merz Aesthetics i...

Merz Pharmaceuticals, LLC

Friedrich Merz began his company in 1908 with his first invention—a patented, water-soluble base for topical therapy. Through a series of additional inventions and subsequent acquisitions, he p...

More Information about "Merz Pharma GmbH & Co. KGaA" on BioPortfolio

We have published hundreds of Merz Pharma GmbH & Co. KGaA news stories on BioPortfolio along with dozens of Merz Pharma GmbH & Co. KGaA Clinical Trials and PubMed Articles about Merz Pharma GmbH & Co. KGaA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Merz Pharma GmbH & Co. KGaA Companies in our database. You can also find out about relevant Merz Pharma GmbH & Co. KGaA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record